Mesenchymal Stem Cell-derived Extracellular Vesicles for Kidney Repair: Current Status and Looming Challenges

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2017 Dec 6

PMID 29202871

Citations 108

Authors

Arash Aghajani Nargesi

Lilach O Lerman

Alfonso Eirin

Affiliations

Soon will be listed here.

Abstract

Novel therapies are urgently needed to address the rising incidence and prevalence of acute kidney injury (AKI) and chronic kidney disease (CKD). Mesenchymal stem/stromal cells (MSCs) have shown promising results in experimental AKI and CKD, and have been used in the clinic for more than a decade with an excellent safety profile. The regenerative effects of MSCs do not rely on their differentiation and ability to replace damaged tissues, but are primarily mediated by the paracrine release of factors, including extracellular vesicles (EVs), composed of microvesicles and exosomes. MSC-derived EVs contain genetic and protein material that upon transferring to recipient cells can activate several repair mechanisms to ameliorate renal injury. Recent studies have shown that MSC-derived EV therapy improved renal outcomes in several animal models of AKI and CKD, including ischemia-reperfusion injury, drug/toxin-induced nephropathy, renovascular disease, ureteral obstruction, and subtotal nephrectomy. However, data about the renoprotective effects of EV therapy in patients with renal failure are scarce. This review summarizes current knowledge of MSC-derived EV therapy in experimental AKI and CKD, and discusses the challenges that need to be addressed in order to consider MSC-derived EVs as a realistic clinical tool to treat patients with these conditions.

Citing Articles

Enhanced therapeutic effects of hypoxia-preconditioned mesenchymal stromal cell-derived extracellular vesicles in renal ischemic injury.

Yuan F, Liu J, Zhong L, Liu P, Li T, Yang K Stem Cell Res Ther. 2025; 16(1):39.

PMID: 39901252 PMC: 11792194. DOI: 10.1186/s13287-025-04166-z.

Platform technologies and human cell lines for the production of therapeutic exosomes.

Kim J, Song Y, Park C, Choi C Extracell Vesicles Circ Nucl Acids. 2024; 2(1):3-17.

PMID: 39698504 PMC: 11648496. DOI: 10.20517/evcna.2020.01.

Targeting cellular senescence in kidney diseases and aging: A focus on mesenchymal stem cells and their paracrine factors.

Hejazian S, Hejazian S, Mostafavi S, Hosseiniyan S, Montazersaheb S, Ardalan M Cell Commun Signal. 2024; 22(1):609.

PMID: 39696575 PMC: 11657437. DOI: 10.1186/s12964-024-01968-1.

Dynamic conditioning of porcine kidney grafts with extracellular vesicles derived from urine progenitor cells: A proof-of-concept study.

Burdeyron P, Giraud S, Lepoittevin M, Jordan N, Brishoual S, Jacquard M Clin Transl Med. 2024; 14(12):e70095.

PMID: 39673122 PMC: 11645449. DOI: 10.1002/ctm2.70095.

Exosomes in nanomedicine: a promising cell-free therapeutic intervention in burn wounds.

Manzoor T, Farooq N, Sharma A, Shiekh P, Hassan A, Dar L Stem Cell Res Ther. 2024; 15(1):355.

PMID: 39385310 PMC: 11462792. DOI: 10.1186/s13287-024-03970-3.

References

Eldh M, Lotvall J, Malmhall C, Ekstrom K . Importance of RNA isolation methods for analysis of exosomal RNA: evaluation of different methods. Mol Immunol. 2012; 50(4):278-86. DOI: 10.1016/j.molimm.2012.02.001. View

Gatti S, Bruno S, Deregibus M, Sordi A, Cantaluppi V, Tetta C . Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant. 2011; 26(5):1474-83. DOI: 10.1093/ndt/gfr015. View

Wang R, Lin M, Li L, Li L, Qi G, Rong R . [Bone marrow mesenchymal stem cell-derived exosome protects kidney against ischemia reperfusion injury in rats]. Zhonghua Yi Xue Za Zhi. 2015; 94(42):3298-303. View

He J, Wang Y, Lu X, Zhu B, Pei X, Wu J . Micro-vesicles derived from bone marrow stem cells protect the kidney both in vivo and in vitro by microRNA-dependent repairing. Nephrology (Carlton). 2015; 20(9):591-600. DOI: 10.1111/nep.12490. View

Hass R, Kasper C, Bohm S, Jacobs R . Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011; 9:12. PMC: 3117820. DOI: 10.1186/1478-811X-9-12. View

Gregorini M, Corradetti V, Pattonieri E, Rocca C, Milanesi S, Peloso A . Perfusion of isolated rat kidney with Mesenchymal Stromal Cells/Extracellular Vesicles prevents ischaemic injury. J Cell Mol Med. 2017; 21(12):3381-3393. PMC: 5706569. DOI: 10.1111/jcmm.13249. View

Peired A, Sisti A, Romagnani P . Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review of Clinical Evidence. Stem Cells Int. 2016; 2016:4798639. PMC: 5046016. DOI: 10.1155/2016/4798639. View

Wang B, Jia H, Zhang B, Wang J, Ji C, Zhu X . Pre-incubation with hucMSC-exosomes prevents cisplatin-induced nephrotoxicity by activating autophagy. Stem Cell Res Ther. 2017; 8(1):75. PMC: 5385032. DOI: 10.1186/s13287-016-0463-4. View

Honeycutt A, Segel J, Zhuo X, Hoerger T, Imai K, Williams D . Medical costs of CKD in the Medicare population. J Am Soc Nephrol. 2013; 24(9):1478-83. PMC: 3752941. DOI: 10.1681/ASN.2012040392. View

10.

Tomasoni S, Longaretti L, Rota C, Morigi M, Conti S, Gotti E . Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev. 2012; 22(5):772-80. PMC: 3578372. DOI: 10.1089/scd.2012.0266. View

11.

Chertow G, Burdick E, Honour M, Bonventre J, Bates D . Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005; 16(11):3365-70. DOI: 10.1681/ASN.2004090740. View

12.

Lai R, Chen T, Lim S . Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen Med. 2011; 6(4):481-92. DOI: 10.2217/rme.11.35. View

13.

Bruno S, Tapparo M, Collino F, Chiabotto G, Deregibus M, Lindoso R . Renal Regenerative Potential of Different Extracellular Vesicle Populations Derived from Bone Marrow Mesenchymal Stromal Cells. Tissue Eng Part A. 2017; 23(21-22):1262-1273. PMC: 5689130. DOI: 10.1089/ten.TEA.2017.0069. View

14.

Choi H, Lee H, Kim B, Ahn S, Jung A, Lee M . Mesenchymal stem cell-derived microparticles ameliorate peritubular capillary rarefaction via inhibition of endothelial-mesenchymal transition and decrease tubulointerstitial fibrosis in unilateral ureteral obstruction. Stem Cell Res Ther. 2015; 6:18. PMC: 4393614. DOI: 10.1186/s13287-015-0012-6. View

15.

Coumans F, Brisson A, Buzas E, Dignat-George F, Drees E, El-Andaloussi S . Methodological Guidelines to Study Extracellular Vesicles. Circ Res. 2017; 120(10):1632-1648. DOI: 10.1161/CIRCRESAHA.117.309417. View

16.

Srisawat N, Kellum J . Acute kidney injury: definition, epidemiology, and outcome. Curr Opin Crit Care. 2011; 17(6):548-55. DOI: 10.1097/MCC.0b013e32834cd349. View

17.

Zhang X, Li Z, Woollard J, Eirin A, Ebrahimi B, Crane J . Obesity-metabolic derangement preserves hemodynamics but promotes intrarenal adiposity and macrophage infiltration in swine renovascular disease. Am J Physiol Renal Physiol. 2013; 305(3):F265-76. PMC: 3742861. DOI: 10.1152/ajprenal.00043.2013. View

18.

Nassar W, El-Ansary M, Sabry D, Mostafa M, Fayad T, Kotb E . Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. Biomater Res. 2016; 20:21. PMC: 4974791. DOI: 10.1186/s40824-016-0068-0. View

19.

Borges F, Melo S, Ozdemir B, Kato N, Revuelta I, Miller C . TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J Am Soc Nephrol. 2013; 24(3):385-92. PMC: 3582210. DOI: 10.1681/ASN.2012101031. View

20.

Meng Y, Eirin A, Zhu X, Tang H, Chanana P, Lerman A . The metabolic syndrome alters the miRNA signature of porcine adipose tissue-derived mesenchymal stem cells. Cytometry A. 2017; 93(1):93-103. PMC: 5756133. DOI: 10.1002/cyto.a.23165. View